The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1555
September 10, 2018
View Complete Issue         Table of Contents 2019 
Obiltoxaximab (Anthim) for Inhalational Anthrax
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Obiltoxaximab (Anthim) for Inhalational Anthrax
September 10, 2018 (Issue: 1555)
The FDA has approved obiltoxaximab (Anthim – Elusys Therapeutics), a toxin-targeting monoclonal antibody, for treatment of inhalational anthrax in combination with antibacterial drugs and prophylaxis of inhalational anthrax when other therapies...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Obiltoxaximab (Anthim) for Inhalational Anthrax
Article code: 1555d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.